Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.

Abstract: The present invention relates to an improved KNN-based 6LoWPAN network intrusion detection method. The present invention selects quantifiable security features which can reflect a self-security state of network elements of a 6LoWPAN network for training, and establishes a 6LoWPAN network feature space. The present invention assigns the weights to the features and transfers zero points, to alleviate the bias caused by large and small impact factors and simplify calculation; realizes construction and update of a state data table of network elements by extracting the feature data of network elements in real time, thus forming a normal contour updated according to the real-time state of the network in the feature space of the 6LoWPAN network based on the clustering effect of a KNN algorithm; and the present invention improves the KNN algorithm and redefines a basis for judging the invasion, to meet the requirements for 6LoWPAN network intrusion detection.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: A system and the method of use for processing a cell therapy product includes a centrifugation container and a rotor generating centrifugal field that extends to the centrifugation container. The centrifugation container has a substantially cylindrically shaped container body and a movable plunger rod. The container body contains cell suspension and the movable plunger rod is configured to have a mixing blade at the end of the movable plunger rod contacting the cell suspension in the container body. The mixing blade on the movable plunger rod generates mixing force applied to the cell suspension when the movable plunger rod is rotated around axis of the container body. The end of the movable plunger rod contacting the cell suspension is also movable in the container body along longitudinal direction of the container body when withdrawing and expelling fluid in and out of the centrifugation container body.

Abstract: A medication injection device comprising a medication container to contain medication; a connector provided with a blocking feature; a push rod having a plurality of teeth disposed along the length, and a spring biasing against the push rod to move proximally. The spring can be compression spring, extension spring, torsion spring, or constant force spring. By enabling or disabling engagement between the blocking feature on the connector and the tooth on the push rod, the push rod is either prevented from moving distally or allowed to move distally. The medication is drawn into the medication container when the push rod moves proximally and the medication is dispensed out of the medication container when the push rod moves distally.

Abstract: A positioning structure of a clamper of a threading machine for a racket contains: a rack, an engagement protrusion, an operation member, and two springs. A fixing holder is erected on a support plate of the threading machine, and the rack includes multiple first teeth, the fixing holder includes an accommodation chamber with an opening. The engagement protrusion is received in the accommodation chamber and includes a toothed extension on which multiple second teeth are formed. The engagement protrusion further includes a recess and an abutting fence. The operation member includes a drive portion and a push portion. The two springs are mounted on a top of the engagement protrusion, and two ends of each spring abut against the engagement protrusion and the fixing holder respectively so that each spring forces the engagement protrusion to engage with the rack.

Abstract: The present application discloses a needle for repairing an alignment layer on a liquid crystal display substrate. The needle includes a needle tip; and a flexible material coating surrounding the needle tip.

Abstract: A drug delivery device includes a housing component having an interior space and an exterior surface, an injection needle having a retracted state wherein the needle is hosted inside of the interior space and a deployed state wherein a pointed end of the needle projects beyond the exterior surface of the housing component, a needle drive mechanism coupled to the needle to move the needle between the retracted and deployed states, and a drug container disposed within the interior space. The drug container is pre-filled with sterile liquid drug and to be in fluid communication with the needle. The sterile liquid drug herein might be solution, suspension, emulation or other forms in fluid state. The drug delivery device also includes a microcontroller coupled to the needle drive mechanism. The microcontroller is configured to control the needle drive mechanism to move the needle between the retracted state and the deployed state. Further, the delivery device is wearable, disposable, and single-use.

Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.

Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.

Abstract: A fasting mimicking diet package providing daily meal portions for a predetermined number of days is provided. The fasting mimicking diet package includes a kale cracker composition, a first vegetable broth composition, a mushroom soup composition, a tomato soup composition, a quinoa-containing minestrone soup composition, a bean-containing minestrone soup composition, and a pumpkin soup composition. Characteristically, the daily meal portions are packaged into meal servings or into a total daily serving to be divided into meals.

Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.

Abstract: The present invention relates to a new method for successfully inducing the mutation of cell chemokine receptor CCR5 gene into CCR5?32 deletion gene by using the CRISPR-Cas9 genome editing technique. CCR5 is an important co-receptor for entry of Human Immunodeficiency Virus (HIV) into human host cells. CCR5?32 deletion is a 32-bp deletion in CCR5 coding region, which results in change and premature termination in the sequence following the 185th amino acid. Biallelic homozygous deletion of CCR5?32 is naturally resistant to HIV infection, i.e., the people carrying this mutation can't be infected by HIV. The present invention uses both lentiviral packaging system and the CRISPR technique to induce CCR5?32 deletion. Due to the characteristics of a wide range of Lentivirus infection, the invention can be applied to cells such as bone marrow stem cells and CD4+ T cells and can be expected to be the therapeutic drug for HIV/AIDS infection or other diseases.

Abstract: A network sharing system includes an outdoor wireless transceiver device, an indoor network sharing device, and a high-speed Ethernet transmission cable. The outdoor wireless transceiver device includes a high-frequency network transceiver module and a first Ethernet port and the high-frequency network transceiver module is connected to the first Ethernet port and is configured to receive a high-frequency network signal. The indoor network sharing device includes a processing module and a second Ethernet port. The high-speed Ethernet transmission cable has a transmission rate above 1 giga bits per second (Gbps), two ends of the high-speed Ethernet transmission cable are respectively connected to a first RJ45 connector and a second RJ45 connector, the high-speed Ethernet transmission cable is provided with a flat cable segment, the first RJ45 connector is connected to the first Ethernet port, and the second RJ45 connector is connected to the second Ethernet port.

Abstract: The present invention relates to a DDoS attack detection and mitigation method for an industrial SDN network, and belongs to the field of network security. According to the method, by means of the cooperation between an east-west interface of an SDN controller in an industrial backhaul network and a system manager of an industrial access network, in conjunction with the features of the industrial backhaul network and an industrial access network data packet, a flow entry matching field of an OpenFlow switch is extended, and a flow table 0 is set to be a “flow table dedicated to DDoS attack mitigation” for defending against an attacking data flow in a timely manner. By using the SDN controller of an industrial backhaul network and a DDoS attack detection and mitigation system, an attacking data flow is identified and a DDoS attack source is found, and the policy of mitigating a DDoS attack is implemented by means of scheduling a system manager of the industrial access network.

Abstract: An ultraviolet (UV) light source is provided. The device uses a high-uniformity diode array. A lens unit of collimated illumination lenses is used. A light source of UV light-emitting diode (UVLED) array is formed and passes through the lens unit to uniformly distribute the light source and obtain a collimated light. The present invention comprises a light source of UVLED array; a collimated illumination lens unit; and a substrate. The construction is simple. The present invention can be applied in the lithography of a semiconductor. The lithography forms contact lines of widths not greater than 3 microns (?m); soft-contact lines of widths of 3˜30 ?m; and short-spaced lines of widths of 30˜200 ?m. The present invention avoids the mask from contact wear-out for multiple uses, and further reduces the replacement rate.

Abstract: A system for detecting an illuminance of the present invention includes a light source, a light sensor, and a signal output module. The light source includes a first A light-emitting diode, the first A light-emitting diode having a first color light; and the light source emits a first ray of light. The light sensor has a sensing face; the light sensor includes a first B light-emitting diode disposed on the sensing face, the first B light-emitting diode having the first color light; and the light sensor receives at least a portion of the first ray of light and generates a first sensing voltage. The signal output module is coupled to the light sensor to receive the first sensing voltage and output a sensing result signal according to the first sensing voltage.